Program
marstacimab
Also written as “PF-06741086”, “MARSTACIMAB” and “Marstacimab PFP”.
Its studies are mostly in Hemophilia A, led by Pfizer.
Furthest: phase 3, since May 2, 201910 company-led studies, 4 open or runningNext primary completion: May 5, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 104 open or running | phase 3since May 2, 2019 | Aug 3, 2015 | May 5, 2027phase 1 · NCT06703606 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 3, 2015First study: phase 1 study in HealthyFirst studyNCT02531815 · 41 enrolled · Belgium
- Nov 23, 2016Phase 2 study in Hemophilia ANCT02974855 · 27 enrolled · United States, Chile, Croatia and more
- Nov 30, 2017Phase 2 study in Hemophilia ANCT03363321 · 20 enrolled · United States, Brazil, Chile and more
- May 2, 2019Phase 3 study in Hemophilia ANCT03938792 · 188 enrolled · United States, Bulgaria, Canada and more
- Mar 26, 2021Phase 1 study in Hemophilia ANCT04832139 · 22 enrolled · Belgium
- Apr 16, 2021Phase 1 study in Hemophilia ANCT04878731 · 6 enrolled · China
- Nov 11, 2021Phase 3 study in Hemophilia ANCT05145127 · 245 planned · United States, Argentina, Australia and more
- Oct 27, 2022Phase 3 study in Hemophilia ANCT05611801 · 100 planned · United States, Argentina, Australia and more
- Nov 21, 2024Phase 1 study in Hemophilia ANCT06703606 · 15 planned · United States, India, Turkey (Türkiye)
- Oct 21, 2026Phase 3 study in Hemophilia ANCT07923981 · 95 planned · United States
Ahead
- May 5, 2027Primary completion: phase 1 study in Hemophilia ANCT06703606
- Sep 10, 2028Primary completion: phase 3 study in Hemophilia ANCT05611801
- Jul 2, 2029Primary completion: phase 3 study in Hemophilia ANCT07923981
- Jul 31, 2030Primary completion: phase 3 study in Hemophilia ANCT05145127
TargetBeta
TFPI →read by rule
“Tissue factor pathway inhibitor inhibitor”ChEMBL 37, by rule
Other programs on TFPI
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| andexanet alfarule | AstraZeneca | phase 4 | 14 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923981Hemophilia A · United States | 3 | Recruiting | Jul 2, 2029 | 95 |
| NCT06703606Hemophilia A · United States, India, Turkey (Türkiye) | 1 | Recruiting | May 5, 2027 | 15 |
| NCT05611801Hemophilia A · United States, Argentina, Australia and more | 3 | Recruiting | Sep 10, 2028 | 100 |
| NCT05145127Hemophilia A · United States, Argentina, Australia and more | 3 | Recruiting | Jul 31, 2030 | 245 |
| NCT04878731Hemophilia A · China | 1 | Completed | Aug 10, 2021 | 6 |
| NCT04832139Hemophilia A · Belgium | 1 | Terminated | Nov 22, 2021 | 22 |
| NCT03938792Hemophilia A · United States, Bulgaria, Canada and more | 3 | Completed | Apr 29, 2025 | 188 |
| NCT03363321Hemophilia A · United States, Brazil, Chile and more | 2 | Completed | Aug 5, 2020 | 20 |
| NCT02974855Hemophilia A · United States, Chile, Croatia and more | 2 | Completed | Dec 3, 2018 | 27 |
| NCT02531815Healthy · Belgium | 1 | Completed | Jul 2016 | 41 |
How it is read
Names in the registry
- “PF-06741086”, 9 entries
- “marstacimab”, 2 entries
- “MARSTACIMAB”, 1 entry
- “Marstacimab PFP”, 1 entry
- “Marstacimab PFS”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.